Indrani Nandy, PhD

Open-Label, Phase 2 Trial of the Oral Neuroactive Steroid GABAA Receptor Positive Allosteric Modulator Zuranolone in Bipolar Disorder I and II

Background: Bipolar disorder (BPD) is a chronic, episodic illness affecting nearly 50 million globally, with disability mostly due to depressive episodes (MDEs). Zuranolone is an investig...

Handan Gunduz-Bruce , MD, MBA;

Abdul Sankoh , PhD;

Jeffrey Jonas , MD;

Indrani Nandy , PhD;

James Doherty , PhD;

Stephen Kanes , MD, PhD;

Robert Lasser , MD, MBA;

10/08/2020

Featured Webinar

Implementing ERAS Protocols Throughout Patient Peri-Op Journey: Reductions in Complications

Upcoming Events

November 23 ⁠–⁠ November 24

December 4 ⁠–⁠ December 5

Great Debates & Updates in Diabetic Foot

December 6 ⁠–⁠ December 7

December 9 ⁠–⁠ December 11

December 12 ⁠–⁠ December 13

December 14 ⁠–⁠ December 15

February 2 ⁠–⁠ February 5

February 27 ⁠–⁠ March 1

March 17 ⁠–⁠ March 19

See Full Calendar

Indrani Nandy, PhD

Featured Webinar

Upcoming Events

Specialties

Events

Year Round Education

HMP Global Products